{"article_title": "Abbott Labs to sell part of generics business for $5.3 billion", "article_keywords": ["sell", "billion", "abbott", "business", "developed", "sales", "53", "roughly", "labs", "pharmaceuticals", "traded", "generics", "branded", "markets"], "article_url": "http://www.marketwatch.com/story/abbott-labs-to-sell-part-of-generics-business-for-53-billion-2014-07-14", "article_text": "Abbott Laboratories said it will sell its developed markets branded generics pharmaceuticals business to Mylan Inc. in a $5.3 billion deal that includes the formation of a new publicly traded company.\n\nAbbott ABT, +1.84% will receive equity ownership of roughly 105 million shares, or about 21%, in a newly formed entity that will combine Mylan\u2019s MYL, +0.57% existing business and Abbott\u2019s developed markets pharmaceuticals business, Abbott said Monday.\n\nThe new entity will be a publicly traded company, Abbott added.\n\nThe developed markets portion of this business generated roughly $2 billion in sales in 2013, the company said, adding that Abbott will retain its branded generics pharmaceuticals business and products in emerging markets, as well as its other businesses and products in developed markets.\n\nThe deal gives Abbott additional strategic flexibility, said Chairman and Chief Executive Miles D. White, adding that the company\u2019s branded generics pharmaceuticals business will focus on emerging markets.\n\nThe transaction is expected to close in the first quarter of 2015, after which, Abbott said it expects its sales growth rate will be 1% higher and the growth rate of its ongoing net income will be more than 2% higher.\n\nAn expanded version of this report appears on WSJ.com\n\nMore from MarketWatch", "article_metadata": {"lifp_basePath": "https://id.marketwatch.com/access", "twitter": {"site": {"id": 624413}, "domain": "marketwatch.com", "image": {"width": 1200, "identifier": "http://mw3.wsj.net/mw5/content/logos/mw_mark.svg", "height": 630}, "card": "summary_large_image", "description": "Abbott Laboratories sells its developed markets branded generics pharmaceuticals business to Mylan in a $5.3 billion deal that includes the formation of a new publicly traded company."}, "article.content_group": "marketwatch", "parsely-author": "Anna Prior", "parsely-type": "post", "parsely-pub-date": "2014-07-14T07:34:00-04:00", "parsely-link": "http://www.marketwatch.com/story/abbott-labs-to-sell-part-of-generics-business-for-53-billion-2014-07-14", "author": "Anna Prior", "parsely-title": "Abbott Labs to sell part of generics business for $5.3 billion", "description": "Abbott Laboratories sells its developed markets branded generics pharmaceuticals business to Mylan in a $5.3 billion deal that includes the formation of a new publicly traded company.", "apple-itunes-app": "app-id=336693422", "article.section": "Industries", "page.site": "marketwatch", "robots": "noarchive,noodp", "fb": {"app_id": 283204329838}, "parsely-section": "MW_Industries", "article": {"publisher": "https://www.facebook.com/marketwatch"}, "viewport": "width=device-width, initial-scale=1, maximum-scale=1", "og": {"site_name": "MarketWatch", "description": "Abbott Laboratories sells its developed markets branded generics pharmaceuticals business to Mylan in a $5.3 billion deal that includes the formation of a new publicly traded company.", "title": "Abbott Labs to sell part of generics business for $5.3 billion", "url": "http://www.marketwatch.com/story/abbott-labs-to-sell-part-of-generics-business-for-53-billion-2014-07-14", "image": "http://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "type": "article"}, "ob": {"image": "http://mw3.wsj.net/mw5/content/logos/mw_logo_social.png"}, "article.id": "920ACC3E-0B49-11E4-B65E-00212803FAD6", "position": 1}, "_id": "\"57477af36914bd0286fcff9f\"", "article_summary": "Abbott Laboratories said it will sell its developed markets branded generics pharmaceuticals business to Mylan Inc. in a $5.3 billion deal that includes the formation of a new publicly traded company.\nAbbott ABT, +1.84% will receive equity ownership of roughly 105 million shares, or about 21%, in a newly formed entity that will combine Mylan\u2019s MYL, +0.57% existing business and Abbott\u2019s developed markets pharmaceuticals business, Abbott said Monday.\nThe deal gives Abbott additional strategic flexibility, said Chairman and Chief Executive Miles D. White, adding that the company\u2019s branded generics pharmaceuticals business will focus on emerging markets.\nThe developed markets portion of this business generated roughly $2 billion in sales in 2013, the company said, adding that Abbott will retain its branded generics pharmaceuticals business and products in emerging markets, as well as its other businesses and products in developed markets.\nThe new entity will be a publicly traded company, Abbott added."}